Plerixafor for patients failing stem cell mobilization a review of the clinical and cost-effectiveness and guidelines
In 2012, the CADTH Common Drug Review (CDR) examined the evidence on plerixafor, consisting of two randomized controlled trials, and issued a "do not list" recommendation based on the exclusion of the subpopulation of interest from the included studies (i.e. predicted poor or proven poor m...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 08 November 2016
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | In 2012, the CADTH Common Drug Review (CDR) examined the evidence on plerixafor, consisting of two randomized controlled trials, and issued a "do not list" recommendation based on the exclusion of the subpopulation of interest from the included studies (i.e. predicted poor or proven poor mobilizers). This Rapid Response report aims to identify and review the clinical and cost-effectiveness of plerixafor in patients who are failing stem cell mobilization. Guidelines associated with the use of plerixafor in patients failing stem cell mobilization will also be examined |
|---|---|
| Item Description: | "CADTH Rapid Response Service." |
| Physical Description: | 1 PDF file (33 pages) |